Last updated: 2026-09-06 11:08:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sarepta Therapeutics,, Inc. (SRPT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $22.51, with a market capitalization of $2.38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.68 to $25.32. This page covers its latest market performance, valuation, price trends and company information.
$2.38B | |
$22.58 | |
$181.83 | |
$3.30 | |
$22.99 | |
2.30M | |
3.34M | |
-- | |
$25.32 | |
$14.68 | |
-- | |
-- |
Sarepta Therapeutics,, Inc. (SRPT) last closed at $22.99 as of 2026-09-04 23:54:00, unchanged from the previous close of $22.99.
During the latest regular trading session, SRPT traded between $3.30 and $181.83, with a volume of 2.30M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Sarepta Therapeutics,, Inc. (SRPT) moved from $21.59 to $22.51, representing a gain of 4.24% ($0.92).
The stock traded between $18.77 and $23.62 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 3.91 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 73.6%
SRPT is currently trading at $22.51, placing it 73.6% of the way from its 52-week low of $14.68 to its 52-week high of $25.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 835 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sarepta Therapeutics,, Inc. (SRPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.